Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

7.25
+0.10501.47%
Volume:61.65K
Turnover:447.09K
Market Cap:734.31M
PE:-7.07
High:7.34
Open:7.22
Low:7.11
Close:7.14
Loading ...

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk

TIPRANKS
·
17 Dec 2024

What’s New in DePin? VanEck Invests in DAWN, IoTeX Blockchain Association, And More

BE[IN]CRYPTO
·
17 Dec 2024

Day One price target lowered to $34 from $39 at JonesResearch

TIPRANKS
·
17 Dec 2024

Why Is Day One Biopharmaceuticals Inc. (DAWN) Among the Best Up and Coming Stocks to Buy According to Analysts?

Insider Monkey
·
27 Nov 2024

Day One Biopharmaceuticals Announces Leadership Transition

TIPRANKS
·
21 Nov 2024

Day One Announces Retirement of DR. Samuel Blackman, Co-Founder and Head of Research & Development

THOMSON REUTERS
·
21 Nov 2024

Press Release: Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Dow Jones
·
21 Nov 2024

U.S. RESEARCH ROUNDUP-BXP, Hubspot, Qualcomm

Reuters
·
07 Nov 2024

Exploring Three High Growth Tech Stocks in the United States

Simply Wall St.
·
06 Nov 2024

Bullish: Analysts Just Made A Huge Upgrade To Their Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Forecasts

Simply Wall St.
·
04 Nov 2024

We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth

Simply Wall St.
·
01 Nov 2024

Day One Biopharm Price Target Maintained With a $33.00/Share by Needham

Dow Jones
·
31 Oct 2024

Ami Fadia Reiterates Buy Rating on Day One Biopharmaceuticals Amid Strong Q3 Performance and Optimistic Future Outlook

TIPRANKS
·
31 Oct 2024

Buy Rating Affirmed for Day One Biopharmaceuticals Amid Strong Ojemda Sales and Strategic Growth Prospects

TIPRANKS
·
31 Oct 2024

Day One Biopharmaceuticals Reports Strong Q3 Growth

TIPRANKS
·
31 Oct 2024

Strong Buy Recommendation for Day One Biopharmaceuticals Driven by Impressive Revenue Growth and Strategic Market Expansion

TIPRANKS
·
31 Oct 2024

Buy Rating Affirmed for Day One Biopharmaceuticals on Strong Ojemda Performance and Pipeline Expansion Prospects

TIPRANKS
·
31 Oct 2024

Day One Biopharmaceuticals, Inc. (DAWN) Surpasses Q3 Earnings and Revenue Estimates

Zacks
·
31 Oct 2024

Stock Track | Day One Biopharma Soars After Smashing Q3 Earnings Estimates

Stock Track
·
31 Oct 2024

Day One Biopharmaceutical Q3 2024 GAAP EPS $0.38 Beats $(0.39) Estimate, Sales $93.761M Beat $23.545M Estimate

Benzinga
·
31 Oct 2024